The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma

被引:3
|
作者
Zhang, Lishuo [1 ]
Di, Longjiang [2 ]
Liu, Jinhui [3 ]
Lei, Xianli [4 ]
Gu, Maoli [1 ]
Zhang, Wenjing [3 ]
Wang, Yufu [3 ]
机构
[1] Harbin Med Univ, Dept Urol, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China
[2] Southern Med Univ, Coll Basic Med, Guangzhou, Guangdong, Peoples R China
[3] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China
[4] Harbin Med Univ, Harbin, Heilongjiang, Peoples R China
基金
中国国家自然科学基金;
关键词
clear cell renal cell carcinoma; long non-coding RNA; cuproptosis; prognosis; immunotherapy; CLASSIFICATION;
D O I
10.3389/fgene.2023.1039813
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cuproptosis is a new form of cell death, the second form of metal ion-induced cell death defined after ferroptosis. Recently, cuproptosis has been suggested to be associated with tumorigenesis. However, the relationship between cuproptosis and patient prognosis in clear cell renal cell carcinoma (ccRCC) in the context of immunotherapy remains unknown. The aim of this study was to investigate the correlation between cuproptosis-related long non-coding RNA (lncRNA) and ccRCC in terms of immunity as well as prognosis. Clinical information on lncRNAs associated with differences in cuproptosis genes in ccRCC and normal tissues was collected from The Cancer Genome Atlas (TCGA) dataset. Univariate Cox regression was used to screen lncRNAs. A total of 11 lncRNAs closely associated with cuproptosis were further screened and established using the least absolute shrinkage and selection operator (LASSO) algorithm and multivariate Cox regression, and the samples were randomly divided into training and test groups. A risk prognostic model was constructed using the training group, and the model was validated using the test group. We investigated the predictive ability of the prognostic risk model in terms of clinical prognosis, tumor mutation, immune escape, immunotherapy, tumor microenvironment, immune infiltration levels, and tumor drug treatment of ccRCC. Using the median risk score, patients were divided into low and high-risk groups. Kaplan-Meier curves showed that the overall survival (OS) of patients in the high-risk group was significantly worse than low-risk group (p < 0.001). Receiver operating characteristic (ROC) curves further validated the reliability of our model. The model consistently and accurately predicted prognosis at 1, 3, and 5 years, with an AUC above 0.7. Tumor cell genes generally precede morphological abnormalities; therefore, the model we constructed can effectively compensate for the traditional method of evaluating the prognosis of patients with renal cancer, and our model was also clinically meaningful in predicting ccRCC staging. In addition, lower model risk scores determined by mutational load indicated a good chance of survival. The high-risk group had greater recruitment of immune cells, while the anti-immune checkpoint immunotherapy was less efficacious overall than that of the low-risk group. Tumor and immune-related pathways were enriched, and anti-tumor agents were selected to improve the survival of ccRCC. This prognostic risk model is based on the levels of cuproptosis-associated lncRNAs and provides a new perspective in the clinical assessment and precise treatment of ccRCC.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] A cuproptosis-related lncRNA signature identified prognosis and tumour immune microenvironment in kidney renal clear cell carcinoma
    Xin, Sheng
    Mao, Jiaquan
    Cui, Kai
    Li, Qian
    Chen, Liang
    Li, Qinyu
    Tu, Bocheng
    Liu, Xiaming
    Wang, Tao
    Wang, Shaogang
    Liu, Jihong
    Song, Xiaodong
    Song, Wen
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [2] Cuproptosis-related lncRNA: Prediction of prognosis and subtype determination in clear cell renal cell carcinoma
    Huili, Youlong
    Nie, Shiwen
    Zhang, Liguo
    Yao, Anliang
    Liu, Jian
    Wang, Yong
    Wang, Lei
    Cao, Fenghong
    FRONTIERS IN GENETICS, 2022, 13
  • [3] Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning
    Bai, Zhixun
    Lu, Jing
    Chen, Anjian
    Zheng, Xiang
    Wu, Mingsong
    Tan, Zhouke
    Xie, Jian
    BIOMOLECULES, 2022, 12 (12)
  • [4] Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma
    Xu, Shengxian
    Liu, Dongze
    Chang, Taihao
    Wen, Xiaodong
    Ma, Shenfei
    Sun, Guangyu
    Wang, Longbin
    Chen, Shuaiqi
    Xu, Yong
    Zhang, Hongtuan
    FRONTIERS IN GENETICS, 2022, 13
  • [5] A novel oxidative-stress related lncRNA signature predicts the prognosis of clear cell renal cell carcinoma
    Zhang, Yu
    Zhou, Guozhong
    Shi, Wei
    Shi, Weili
    Hu, Meijun
    Kong, Defu
    Long, Rong
    Chen, Nan
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [6] A novel oxidative-stress related lncRNA signature predicts the prognosis of clear cell renal cell carcinoma
    Yu Zhang
    Guozhong Zhou
    Wei Shi
    Weili Shi
    Meijun Hu
    Defu Kong
    Rong Long
    Nan Chen
    Scientific Reports, 13
  • [7] A novel stemness-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity of clear cell renal cell carcinoma
    Liu, Jia
    Yao, Lin
    Yang, Yong
    Ma, Jinchao
    You, Ruijian
    Yu, Ziyi
    Du, Peng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [8] Identification and validation of a novel cuproptosis-related lncRNA signature for prognosis and immunotherapy of head and neck squamous cell carcinoma
    Xu, Qiu-Shuang
    Shen, Zheng-Zhong
    Yuan, Ling-Qing
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [9] A Metastasis-Related lncRNA Signature Correlates With the Prognosis in Clear Cell Renal Cell Carcinoma
    Dou, Qian
    Gao, Shun
    Gan, Hua
    Kang, Zhao
    Zhang, Han
    Yang, Yichun
    Tong, Hang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] LncRNA CRNDE is a biomarker for clinical progression and poor prognosis in clear cell renal cell carcinoma
    Ding, Chenguang
    Han, Feng
    Xiang, Heli
    Xia, Xinxin
    Wang, Yuxiang
    Dou, Meng
    Zheng, Jin
    Li, Yang
    Xue, Wujun
    Ding, Xiaoming
    Tian, Puxun
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (12) : 10406 - 10414